Advances in Therapy

, Volume 26, Issue 4, pp 369–382

Update on smoking cessation therapies

  • Deirdre A. Glynn
  • John F. Cryan
  • Pauline Kent
  • Robert A. Flynn
  • Marcus P. Kennedy
Review

DOI: 10.1007/s12325-009-0022-9

Cite this article as:
Glynn, D.A., Cryan, J.F., Kent, P. et al. Adv Therapy (2009) 26: 369. doi:10.1007/s12325-009-0022-9

Abstract

As a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.

Keywords

antidepressantbupropionchronic obstructive pulmonary diseaseischemic heart diseaselung cancernicotinesmokingtobaccovaccinationvarenicline

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  • Deirdre A. Glynn
    • 1
  • John F. Cryan
    • 2
  • Pauline Kent
    • 1
  • Robert A. Flynn
    • 1
  • Marcus P. Kennedy
    • 1
  1. 1.Department of Medicine, Sligo General HospitalThe Mall, Co. SligoSligoRepublic of Ireland
  2. 2.Department of Pharmacology and Therapeutics, School of PharmacyUniversity College CorkCorkRepublic of Ireland